Qiagen and Max Planck team up for test predicting risk of latent TB progression
This article was originally published in Clinica
Molecular diagnostics firm Qiagen and the Max Planck Institute for Infection Biology are developing a test to predict the risk of latent tuberculosis infection progressing to active disease. The new test should become available in 2013 or later, and will be commercialised by Qiagen. Financial terms of the deal were not disclosed.